两种化疗方案治疗晚期老年食管鳞癌的效果比较(1)
[摘要]目的 探讨两种化疗方案治疗晚期老年食管鳞癌的效果及对相关细胞因子的影响。方法 选取2015年8月～2018年8月我院收治的96例晚期老年食管鳞癌患者，根据随机数字表法分为对照组(n=48)和研究组(n=48)。对照组给予顺铂联合氟尿嘧啶化疗方案，研究组给予多西他赛联合顺铂化疗方案，比较两组治疗后临床缓解率，比较两组治疗前后相关细胞因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)以及可溶性MHC-I分子链相关基因A(sMICA)]水平，记录两组不良反应发生情况。结果 研究组治疗后临床缓解率为64.58%(31/48)，显著高于对照组的41.67%(20/48)(P<0.05)。两组治疗前CRP、IL-6、IL-8及sMICA比较，差异无统计学意义(P>0.05)；两组治疗3个疗程后上述指标均较治疗前降低，且研究组低于对照组，差异有统计学意义(P<0.05)。研究组骨髓抑制、胃肠道反应、肝功能异常等不良反应发生率均低于对照组，差异有统计学意义(P<0.05)。结论 多西他赛联合顺铂治疗晚期老年食管鱗癌效果显著，可有效改善相关细胞因子水平，降低不良反应发生率，具有一定的临床应用价值。
[关键词]多西他赛；顺铂；老年食管鳞癌；效果；细胞因子；影响
[中图分类号] R735.1 [文献标识码] A [文章编号] 1674-4721(2019)5(b)-0080-04
[Abstract] Objective To investigate efficacy of two chemotherapy regimens in the treatment of advanced elderly esophageal squamous cell carcinoma and their effects on related cytokines. Methods 96 elderly patients with esophageal squamous cell carcinoma who treated in our hospital from August 2015 to August 2018 were selected. Patients were divided into control group (n=48) and study group (n=48) according to the random number table method. Patients in control group were given chemotherapy regimen of Cisplatin combined with Fluorouracil. Patients in study group were given chemotherapy regimen of Docetaxel combined with Cisplatin. The clinical remission rate of the two groups were compared. The levels of cytokines(C-reactive protein [CRP]， interleukin-6 [IL-6]， interleukin-8 [IL-8] and soluble MHC-I chain-related gene A [sMICA]) were compared before and after treatment. The adverse reactions were recorded. Results The clinical remission rate after treatment in the study group was 64.58% (31/48)， significantly higher than 41.67% (20/48) in the control group (P<0.05). There was no significant difference in CRP， IL-6， IL-8 and sMICA between the two groups before treatment (P>0.05)， and the above indexes were lower in the study group than that in the control group after three courses of treatment (P<0.05). The incidence of adverse reactions such as nausea and vomiting， myelosuppression， abnormal liver function in the study group were lower than those in the control group (P<0.05). Conclusion Docetaxel combined with Cisplatin in the treatment of advanced elderly esophageal squamous cell carcinoma has a significant effect， can effectively improve the levels of related cytokines， reduce the incidence of adverse reactions， has a certain clinical value.
[Key words] Docetaxel； Cisplatin； Elderly esophageal squamous cell carcinoma； Effect； Cytokines； Influence, 百拇医药(余静仪 鲍扬漪)
[关键词]多西他赛；顺铂；老年食管鳞癌；效果；细胞因子；影响
[中图分类号] R735.1 [文献标识码] A [文章编号] 1674-4721(2019)5(b)-0080-04
[Abstract] Objective To investigate efficacy of two chemotherapy regimens in the treatment of advanced elderly esophageal squamous cell carcinoma and their effects on related cytokines. Methods 96 elderly patients with esophageal squamous cell carcinoma who treated in our hospital from August 2015 to August 2018 were selected. Patients were divided into control group (n=48) and study group (n=48) according to the random number table method. Patients in control group were given chemotherapy regimen of Cisplatin combined with Fluorouracil. Patients in study group were given chemotherapy regimen of Docetaxel combined with Cisplatin. The clinical remission rate of the two groups were compared. The levels of cytokines(C-reactive protein [CRP]， interleukin-6 [IL-6]， interleukin-8 [IL-8] and soluble MHC-I chain-related gene A [sMICA]) were compared before and after treatment. The adverse reactions were recorded. Results The clinical remission rate after treatment in the study group was 64.58% (31/48)， significantly higher than 41.67% (20/48) in the control group (P<0.05). There was no significant difference in CRP， IL-6， IL-8 and sMICA between the two groups before treatment (P>0.05)， and the above indexes were lower in the study group than that in the control group after three courses of treatment (P<0.05). The incidence of adverse reactions such as nausea and vomiting， myelosuppression， abnormal liver function in the study group were lower than those in the control group (P<0.05). Conclusion Docetaxel combined with Cisplatin in the treatment of advanced elderly esophageal squamous cell carcinoma has a significant effect， can effectively improve the levels of related cytokines， reduce the incidence of adverse reactions， has a certain clinical value.
[Key words] Docetaxel； Cisplatin； Elderly esophageal squamous cell carcinoma； Effect； Cytokines； Influence, 百拇医药(余静仪 鲍扬漪)